W
WILEX
WILEX is a biopharmaceutical company developing drugs and diagnostic agents to detect and treat malignant tumors and cancers.
About WILEX
Wilex AG is a biopharmaceutical company specializing in the development of diagnostic and therapeutic products for oncology. The company primarily serves healthcare providers, research institutions, and pharmaceutical companies. Operating in the biotechnology and pharmaceutical markets, Wilex focuses on creating targeted therapies and imaging solutions that improve the precision of cancer treatment. The business model revolves around research and development, clinical trials, and partnerships with other biotech firms. Revenue is generated through product sales, licensing agreements, and collaborative research funding.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2001
- Headquarters
- Ladenburg, Germany
- Employees
- 27
- Open positions
- None listed
- Dealroom signal
- 26.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Nov 2010
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| FundingOther financing | Mar 2010 | $27M | — | Undisclosed | — |
| IPOOther financing | Nov 2006 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for WILEX is 0 monthly website visits. WILEX's team declined 47.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 Repron TherapeuticsEpigenetic silencing platform for tumor recurrence repression |
Milan, Italy | Operational | 1 | $2.2M | $8.8M |
 PrecirixCamelid-derived radiopharmaceuticals for targeted cancer therapy |
Jette, Belgium | Operational | |||
 RayzeBioDefeating cancer with radiopharmaceutical medicines |
San Diego, United States | Acquired | |||
 CellmAbsCellmabs is focused on researching and developing innovative biopharmaceuticals for the treatment of cancer |
Óbidos, Portugal | Acquired | |||
 ADCendoA Copenhagen-based biotech company dedicated to developing highly differentiated antibody-drug conjugates (ADCs) for the treatment of underserved cancers |
Copenhagen, Denmark | Operational | |||
 Mediphage BioceuticalsCures for chronic diseases |
Toronto, Canada | Operational | |||
 AutolusProgrammed T-cell immunotherapies for cancer and autoimmune diseases |
London, United Kingdom | Operational | |||
 SerenexDrug discovery and development company that is focused on oncology |
Durham, United States | Acquired |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
TVM Capital Life Science
Apax Partners
Earlybird Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about WILEX on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See WILEX’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.